Funding for this research was provided by:
Received: 20 December 2021
Accepted: 24 July 2022
First Online: 13 August 2022
: Before initiation of the study, the protocol and the informed consent form were reviewed and approved by institutional review boards or independent ethics committees for each of the study sites (Bellberry Limited, Land Salzburg; Fakultni Nemocnice BRNO; Ministry for National Education, Higher Education Research; Albert-Ludwigs-Unversitat Freiburg; Baby Jesus Children’s Hospital; Cincinnati Childrens Hospital Med Ctr; Ann & Robert H. Lurie Children’s Hospital and Northwestern University; Istituto Dermopatico dell’Immacolata).
: Not applicable.
: ASP is an investigator and consultant for Krystal Biotech, a consultant for Amryt, and on the Data Safety Monitoring Board for for Abeona and Inmed. EP is the inventor of the iscorEB instrument. She has no other conflicts of interest to disclose. DRudin, AM, are employees of Phoenix Tissue Repair, a member of the BridgeBio family. DRamsdell, RJ, and HL were employees of Phoenix Tissue Repair, a member of the BridgeBio family, at the time of this manuscript preparation. DFM has been an investigator and consultant for Shire, Amryt, Castle Creek Biosciences, and Scioderm/Amicus and is the inventor of the QOLEB and EBDASI outcome measures.